Aug 17, 2022 / 01:00PM GMT
Operator
Welcome to the Coloplast interim financial statements for 9M 2021, '22. (Operator Instructions)
With that, I'll hand the floor to our speakers. Please begin your meeting.
Kristian Villumsen - Coloplast A/S-President&CEO
Good afternoon, and welcome to our Q3 '21/'22 Conference Call. My name Kristian Villumsen. I'm the CEO of Coloplast. And I'm joined by our CFO, Anders Lonning-Skovgaard; and our Investor Relations team. We'll start like we usually do with a short presentation by Anders and myself, and then open up for questions from you.
Please turn to Slide #3. In Q3, we delivered 8% organic growth and an EBIT margin before special items of 30%. We delivered a respectable return on invested capital of 26% after tax and before special items, impacted by the acquisition of Atos Medical. Reported growth in Danish kroner was 21%. Atos Medical contributed 9 percentage points to the reported growth and delivered double-digit underlying growth.
Before I dive into today's results, I'd
Q3 2022 Coloplast A/S Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
